Clinical Trial for the Safety and Efficacy of NKG2D CAR-T Cell Therapy for Patients With Relapsed and/or Refractory Acute Myeloid Leukemia
Latest Information Update: 02 Nov 2021
At a glance
- Drugs Anti-natural killer group 2D CAR-T cell therapy-Yake Biotechnology (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 14 Dec 2020 New trial record